arrow
A

Alexandre Puissant

Université Paris-Cité
H指数:39
被引数:5,170

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oncogenic modulation of MAPK signaling in leukemia via SPNS2-driven sphingolipid metabolism and membrane nanodomains remodeling

通过SPNS2驱动的鞘脂代谢和膜纳米域重塑对白血病中MAPK信号通路的致癌性调控

2026-10-280
OAAI
FANCM is required for the PAX3::FOXO1-driven oncogenic program in rhabdomyosarcoma

FANCM在横纹肌肉瘤中对于PAX3::FOXO1驱动的癌基因程序是必需的

2026-09-010
OAAI
Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia

剪接相关网络PAK1-CLK1/4-SRRM1是人类和小鼠急性髓系白血病克服化疗耐药的易感靶点

2026-07-080
PRE
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge

EGFR抑制剂抗性肺癌对一种共价、半胱氨酸非依赖性的KEAP1寡聚化分子桥具有交叉敏感性

2026-01-140
OAAI
Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemia

通路共必需性分析显示,复合物II对于急性髓系白血病中的从头嘌呤生物合成是必需的。

2025-12-050
OAAI
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms

JAK2 抑制介导了骨髓增殖性肿瘤中 RAS 通路突变的克隆选择。

2025-07-080
OAAI
Targeting a lineage-specific PI3Kγ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule

使用异双功能降解剂分子靶向急性髓性白血病中的谱系特异性PI3Kγ-Akt信号模块

2024-05-302
PRE
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia FLT3-ITD patients
2023-02-165
OAAI
Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively
2023-01-013
OAAI
Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
2022-09-236
OAAI
A multiparametric niche-like drug screening platform in acute myeloid leukemia
2022-06-249
OAAI
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia
2022-06-0620
OA
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia
LEUKEMIA
IF13.4
2022-04-2637
OA